<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815046</url>
  </required_header>
  <id_info>
    <org_study_id>Botox-Bulkamid study</org_study_id>
    <nct_id>NCT02815046</nct_id>
  </id_info>
  <brief_title>Mixed Urinary Incontinence Symptoms Before and After Treatment With Botox and Bulkamid</brief_title>
  <official_title>Prospective, Non-randomized, Single-center Observational Study of Outcome Measures of Patients Suffering From Mixed Urinary Incontinence Before and After Surgical Procedure With Botulinum Toxin and Polyacrylamide Hydrogel (PAHG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Volker Viereck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital, Frauenfeld</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares mixed urinary incontinence symptoms before and after a combined treatment
      with Botox and Bulkamid. Eligible for the study are adult females with a mixed urinary
      incontinence, having both urgency urinary symptoms and stress urinary symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rates for stress urinary incontinence (SUI)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with negative cough stress test and 90 % improved SUI-visual analog scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in number of micturitions per day</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of complications</measure>
    <time_frame>intra-operative and post-operative follow-up up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of cough stress test levels</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>3 Levels: negative, only a few drops of urine, severe loss of urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUI-visual analog scale</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Scale from 0-10: 0-no suffering - 10-severe suffering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UUI-visual analog scale</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Scale from 0-10: 0-no suffering - 10-severe suffering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of micturitions per day</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of urgency episodes per day</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of urgency urinary incontinence episodes per 3 days</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine volume per micturition</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mixed Incontinence, Urge and Stress</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.</description>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polyacrylamide hydrogel</intervention_name>
    <description>Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.</description>
    <other_name>Bulkamid</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mixed urinary incontinence (MUI) eligible for an intervention with Botox and
        Bulkamid.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged â‰¥ 18 years.

          2. Clinically diagnosed therapy-refractory mixed urinary incontinence (MUI) based on
             cough test, urodynamic evaluation, 3-day micturition diary, incontinence-questionnaire
             with visual analog scales for SUI and UUI.

          3. All criteria for the indication to treat patient with Botox are met.

          4. All criteria for the indication to treat patient with Bulkamid are met.

          5. Participant has given informed consent

        Exclusion Criteria:

          1. All contraindications for Bulkamid or Botox

          2. Previous treatment with Botulinum toxin (within last 3 months)

          3. Previous treatment with Bulkamid or other bulking agent (within last 3 months)

          4. Participant is pregnant or lactating

          5. Current urinary tract infection (in which case this has to be treated first before
             patient might be included)

          6. Residual urine of &gt; 100 ml
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Viereck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital, Frauenfeld</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volker Viereck, MD</last_name>
    <email>volker.viereck@stgag.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cantonal Hospital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Viereck, MD</last_name>
      <email>volker.viereck@stgag.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital, Frauenfeld</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Volker Viereck</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>urgency urinary incontinence</keyword>
  <keyword>stress urinary incontinence</keyword>
  <keyword>Botulinum toxin A</keyword>
  <keyword>Bulkamid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication in peer-reviewed journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

